Dr. Sean Teller is a Principal Engineer at Veryst Engineering, a technical consulting firm in the Boston area. Dr. Teller has extensive experience in testing and modeling the mechanical behavior of materials to help clients improve product performance, understand failure modes, and manufacture robust, high-performing devices.  He consults in medical devices and technology, combination products, consumer products, automotive, and consumer electronics industries, and applies his knowledge of polymer material behavior and failure to help clients solve their R&D and design problems. 

Dr. Teller’s consulting focuses on polymer material testing, material modeling for finite element (FE) simulations and failure analysis. He has extensive experience in advanced FE modeling, and often solves problems involving sealing and leakage, ageing and degradation of materials, design verification studies of engineered systems, verification and validation studies, and manufacturing and assembly of medical devices and combination products. Dr. Teller earned his Ph.D. in Solid Mechanics from Brown University, where he worked on a project to characterize the high-frequency mechanical behavior of soft tissues for tissue engineering applications.

Elizabeth is an Assistant Professor (tenure track) at Montana State University- Mark & Robyn Jones College of Nursing in Bozeman, Montana. She teaches Design of Healthcare Delivery Systems, which is an interprofessional graduate course offering with College of Nursing (Clinical Nurse Leader and DNP students) and College of Engineering students (industrial, mechanical, healthcare systems engineering students) to evaluate quality and efficiency in the delivery of patient care. Her research includes technology innovation and digital health device development for clinical trial participant safety management, with funding awarded from the Montana State University/U.S. Economic Development Administration, American Nurses Association, NIH, Genentech Innovation Fund, and via the National Science Foundation- National Innovation Corps program. She is part of the Blueprint Engine- Tough Tech Program at MIT. Her service includes Chair for the Research Committee of the International Association of Clinical Research Nurses, President-Elect for the Nursing Institute of Healthcare Design, Coalition for Health AI Health System Advisory Board, and a member of the American Nurses Association Innovation Advisory Committee for Technology + Medical Devices. Prior to her current role at Montana State University, Elizabeth was a clinical research nurse, clinical trial manager, and global early clinical development manager spanning hospital and industry roles supporting pediatric diabetology/endocrinology and adult oncology.

Laura Russell is a visionary leader in the life sciences and technology sectors, with expertise in product development and operational excellence. As SVP, Head of Data and AI Product Development at Advarra, she defines and oversees the company’s business transformation through the responsibly guided integration of AI, delivering advanced analytics solutions and novel applications of AI across Advarra’s portfolio of services and technologies.

Previously, Laura held transformative leadership roles at Verily and 23andMe, where she launched impactful products and built scalable operational frameworks. Holding a Master of Science in Clinical and Translational Research from Georgetown University, Laura combines deep industry knowledge with a commitment to advancing healthcare through data-driven and AI-powered solutions.

TBA

TBA

TBA

TBA

Dr Charles Theuer has been Chief Medical Officer at Halozyme since 2024 and is responsible for providing leadership and guidance to Halozyme and its partners/collaborators in subcutaneous drug development with ENHANZE® technology and auto-injectors. Dr Theuer leads clinical development, regulatory affairs, drug safety, medical affairs and bioanalytical and non-clinical sciences strategy and operations, including interactions with regulatory authorities.

Before joining Halozyme, Dr Theuer served as Chief Executive Officer, Chief Medical Officer, and Director of TRACON Pharmaceuticals, where he worked to transform outcomes for cancer patients and optimize clinical development operations. His career includes senior medical leadership positions at TargeGen Inc. where, as Chief Medical Officer, he directed the development of Inrebic®, Pfizer where he led the clinical development of Sutent® in renal cell carcinoma and IDEC Pharmaceuticals where he oversaw clinical trials of Rituxan® and Zevalin®. Charles practiced as a board-certified general surgeon for more than 10 years.

Dr Theuer earned his B.S. in Molecular Biology from the Massachusetts Institute of Technology and his M.D. from the University of California, San Francisco. He received his PhD in epidemiology from the University of California, Irvine, and completed his general surgery residency at Harbor-UCLA Medical Center.